Does ENZALUTAMIDE Cause Hyperlipidaemia? 7 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Hyperlipidaemia have been filed in association with ENZALUTAMIDE (Xtandi). This represents 0.0% of all adverse event reports for ENZALUTAMIDE.
7
Reports of Hyperlipidaemia with ENZALUTAMIDE
0.0%
of all ENZALUTAMIDE reports
1
Deaths
3
Hospitalizations
How Dangerous Is Hyperlipidaemia From ENZALUTAMIDE?
Of the 7 reports, 1 (14.3%) resulted in death, 3 (42.9%) required hospitalization.
Is Hyperlipidaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Malignant neoplasm progression (4,696)
Prostatic specific antigen increased (3,731)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
What Other Drugs Cause Hyperlipidaemia?
ALENDRONATE (511)
AMLODIPINE (226)
DENOSUMAB (204)
SITAGLIPTIN (186)
METHOTREXATE (184)
ROSUVASTATIN (179)
PREDNISONE (169)
FINASTERIDE (145)
MYCOPHENOLATE MOFETIL (141)
ASPIRIN (138)
Which ENZALUTAMIDE Alternatives Have Lower Hyperlipidaemia Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE